Biotech developing FcRn-inhibitor antibodies for autoimmune diseases, competing in the same class as argenx's Vyvgart.
Biotech developing FcRn-inhibitor antibodies for autoimmune diseases, competing in the same class as argenx's Vyvgart.
Has no product to sell, so its costs are paid from money raised from investors; Roivant, the company that founded it, is the largest shareholder. Its value rests on clinical-trial results for IMVT-1402, which it has put ahead of batoclimab, before any route to market through approval and later sales.
Moat: narrow (IP / patents). A differentiated, potentially self-administered FcRn inhibitor competing against an already-approved class leader.
Headquarters: New York, New York, US · Founded: 2018 · Employees: 315
Size Immunovant (IMVT) is a United States Health Care company (Biotechnology) with a market value of $6.86B, the 967th largest of 3,085 United States companies the cockpit tracks. Shares closed at $33.17 on 18 Nov 2026.
Performance Over six months the shares fell 6.7%, against +10.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.
Short interest Short interest is 9.0% of the free float (30 Oct 2026).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$378,000 | -$409,000 | -$377,000 | -$231,000 | -$1.32M |
| EBITDA | -$538M | -$532M | -$438M | -$270M | -$207M |
| Net income | -$509M | -$506M | -$414M | -$259M | -$211M |
| Free cash flow | -$395M | -$407M | -$377M | -$215M | -$188M |
| Capital expenditure | $8,000 | $8,000 | $759,000 | $360,000 | $197,000 |
| Total debt | $0 | $72,000 | $98,000 | $138,000 | $1.57M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Immunovant IMVT | $6.86B | -7% | n/a | n/a | n/a | n/a |
| argenx SE Sponsored ADR ARGX | $59.1B | +17% | +71% | 29% | 10.3× | 11.7% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
| Biohaven BHVN | $1.95B | +46% | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IMVT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.0% | -9.3% | 5th highest of 21 |
| 6-month return | -6.7% | +10.3% | 6th lowest of 21 |
| Distance from 52-week high | -27.0% | -34.3% | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 8.0× | n/a | n/a |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | 11.3× | 47.2% | +16.6% |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | 16.2× | n/a | n/a |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 9.8× | 36.9% | +19.8% |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 35.1× | 24.6% | +38.5% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 18.0× | 13.1% | +26.0% |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 4.8× | 25.9% | +16.4% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 3.7× | 6.2% | +2.3% |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |